Evidence map›Paper›PMID 40782054›Full record

ArticleBioconjugate chemistry2025

Harnessing Fc-Directed Bioconjugation for the Synthesis of Site-Specifically Modified Radioimmunoconjugates.

Camilla Grimaldi, Joni Sebastiano, Wei-Siang Mark Kao, Emilia Strugala, Shane A McGlone, Tomohiro Watanabe, Tsubasa Aoki, Tomohiro Fujii, Brian M Zeglis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Camilla GrimaldiDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065-5024, United States.
Joni SebastianoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065-5024, United States.
Wei-Siang Mark KaoDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065-5024, United States.
Emilia StrugalaDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065-5024, United States.
Shane A McGloneDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065-5024, United States.
Tomohiro WatanabeAjinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.
Tsubasa AokiAjinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.
Tomohiro FujiiAjinomoto Co., Inc., 1-1, Suzuki-Cho, Kawasaki-Ku, Kawasaki-Shi, Kanagawa 210-8681, Japan.
Brian M ZeglisDepartment of Chemistry, Hunter College, The City University of New York, New York, New York 10065-5024, United States.ORCID 0000-0002-9091-744X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-TrastuzumabR01CA204167 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S., ULANER, GARY ALLAN · 2016 to 2020
$3.4M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancerR01CA281801 · NCI · FRED HUTCHINSON CANCER CENTER · PI Delphine L Chen, PAUL D. LAMPE · 2023 to 2026
$2.4M
ImmunoPET Probes for the Imaging of Lyme DiseaseR01AI175417 · NIAID · HUNTER COLLEGE · PI Maria Gomes-Solecki, WEIGANG QIU · 2023 to 2026
$2.2M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
Targeting DNA Mismatches for Auger Electron RadiotherapyR21CA280595 · NCI · HUNTER COLLEGE · PI HUMM, JOHN L, ZEGLIS, BRIAN MATTHEW · 2023 to 2023
$458k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204167NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS R01 CA281801NCI NIH HHS R21 CA280595NIAID NIH HHS R01 AI175417
6 · The paper itself

Abstract

A growing body of preclinical and clinical evidence has shown that site-specifically and site-selectively modified immunoconjugates exhibit improved

Indexed as

ImmunoconjugatesAnimalsCell Line, TumorHumansLutetiumMiceMice, NudeRadioisotopesTissue DistributionImmunoconjugatesLutetiumLutetium-177Radioisotopes

Identifiers

PMID40782054
PMCPMC12371682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.